微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Short Bowel Syndrome
Short Bowel Syndrome

消化

关键词消化 疾病 临床疾病

词汇介绍

拓展阅读

解析

short 英 [ʃɔ:t] 美 [ʃɔ:rt]

释义   adj. 短的;不足的;矮的,低的

n. 短;缺乏;短路;短裤

adv. 不足;突然;唐突地 

例句   Short-term successful outcomes have been described.

已经描述了短期成功的结果。

 

bowel 英 [ˈbaʊəl] 美 [ˈbaʊəl, baʊl]

释义   n. 肠;内部;同情

vt. 将……的肚肠取出

例句   Bowel dilatation was diagnosed when small bowel diameter exceeded 7 mm or large bowel diameter exceeded 18 mm.

肠扩张的诊断根据小肠直径超过7 mm或者大肠直径超过18 mm。

 

syndrome 英 [ˈsɪndrəʊm] 美 [ˈsɪndroʊm]

释义   n. [临床] 综合症状;并发症状;校验子;并发位

例句   Anterior capsular phimosis syndrome.

前囊膜收缩综合征。


概述

短肠综合征,是指大段小肠切除后,残存的功能性肠管不能维持病人营养需要的吸收不良综合征。本病常发生于广泛的肠切除后,常见病因有肠扭转、腹内外疝绞窄、肠系膜血管栓塞或血栓形成等。此外,较长肠段的功能损害如放射性肠炎,或不适当的外科手术如空肠结肠吻合或胃回肠吻合,也可产生类似的临床综合征。 病理生理十二指肠、近端空肠和远端回肠是小肠消化吸收的主要场所,所以只要保留这些部位,即使切除中段小肠长度达50%,病人仍可良好生存。回育瓣和结肠在减慢肠内容运行方面起着重要作回盲瓣和结肠在减慢肠内容运

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials复制标题

肠内自主和休息日肠外支持替杜鲁肽治疗短肠综合征的STEPS试验

发表时间:2019-08-18

影响因子:4.1

作者: Douglas L. Seidner

期刊:J Parenter Enteral Nutr

The clinical features of intestinal failure associated with short bowel syndrome (SBS-IF), including parenteral support (PS; parenteral nutrition, and/or intravenous fluids) volume needs, vary according to the extent and cause of intestinal resection and residual anatomy.1-3 Teduglutide, a glucagon-like peptide (GLP)-2 analogue, is approved in the United States and Europe for the treatment of patients aged 1 year with SBS-IF,4,5 and has been shown to improve intestinal absorption and reduce PS requirements in patients with SBS-IF.6-8 In the phase III, 24-week, placebo controlled STEPS study (NCT00798967; EudraCT, 2008- 006193-15), individual patient response to teduglutide in terms of PS volume reduction was variable, with PS volume change from baseline at week 24 ranging from –1993 to 329 mL/d.2 Recently, Jeppesen et al evaluated clinical and disease characteristics associated with PS volume reduction with teduglutide treatment in patients from the STEPS study.2 Among all patients treated with teduglutide, absolute baseline PS volume requirements were significantly correlated with absolute PS volume reduction; no correlation was seen among placebo-treated patients. Compared with other remnant bowel anatomies, patients with a jejunostomy or ileostomy and no colon remaining had the highest PS volumes at baseline and experienced the greatest PS volume reductions with teduglutide. Compared with vascular or other causes of SBS-IF, patients with inflammatory bowel disease (IBD) as a cause of SBS-IF had higher PS volume requirements at baseline and experienced the greatest PS volume reductions with teduglutide.

译文

与短肠综合征(SBS-IF)相关的肠功能衰竭的临床特征,包括肠外支持(PS;肠外营养和/或静脉输液)的体积需求,根据肠切除和残余解剖的程度和原因而变化。 -3 Teduglutide,一种胰高血糖素样肽(GLP)-2类似物,在美国和欧洲被批准用于治疗患有SBS-IF的1岁患者,4,5并且已被证明可改善肠道吸收并减少SBS-IF.6-8患者的PS要求在III期,24周,安慰剂对照的STEPS研究(NCT00798967; EudraCT,2008-006193-15)中,个体患者对PS剂量减少的teduglutide反应是可变的在第24周,PS体积从基线变化到-1993到329 mL / d。最近,Jeppesen等人评估了STEPS研究患者使用teduglutide治疗PS减少相关的临床和疾病特征.2在所有患者中Ť以teduglutide为例,绝对基线PS体积要求与绝对PS体积减少显着相关;安慰剂治疗的患者之间没有相关性。与其他残余肠解剖结构相比,空肠造口术或回肠造口术并且没有结肠残留的患者在基线时具有最高的PS体积并且经历了用teduglutide最大的PS体积减少。与SBS-IF的血管或其他原因相比,作为SBS-IF原因的炎性肠病(IBD)患者在基线时具有更高的PS体积需求并且经历了用teduglutide最大的PS体积减少。